Beschreibung:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>To evaluate myocardial injury and infarction (MI) following elective percutaneous coronary intervention (PCI).</jats:p></jats:sec><jats:sec><jats:title>Background</jats:title><jats:p>The substantially higher analytical power of high‐sensitivity troponin (hsTn) assays allows detection of minor cardiac troponin (cTn) levels, which may be useful in monitoring myocardial injury and guiding therapies.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Serial hsTnT measurements were conducted in patients undergoing elective PCI and were related to the extent of coronary artery disease (CAD) as reflected by the SYNTAX score risk categories and American College of Cardiology/American Heart Association classification of coronary lesions. Myocardial injury and MI were diagnosed according to the second and third versions of universal MI definition.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The study population consisted of 530 patients, who were grouped into low (41.3%), intermediate (35.4%), and high (23.3%) SYNTAX risk categories. The treated coronary lesions were classified into A 7.8%, B1 24.1%, B2 21.1%, C1 24.6%, and C2 22.4%. Postprocedural hsTnT increases correlated significantly with the complexity of treated coronary lesions (<jats:italic>p</jats:italic> < .05) and CAD magnitude (<jats:italic>p</jats:italic> < .05). Rates of MI type 4a according to the second and third MI definition criteria were 98 (27.5%) and 15 (4.2%) cases in patients with normal baseline hsTnT values (<jats:italic>N</jats:italic> = 357, 67.4%), as well as 137 (79.2%) and 27 (15.6%) cases in those with elevated baseline hsTnT values (<jats:italic>N</jats:italic> = 173, 32.6%), respectively.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>After elective PCI, cTn releases correlate significantly with lesion complexity and CAD extent. Use of hsTnT assay enables precise monitoring of PCI‐related myocardial injury and may identify patients at higher risk for ischemic events, who may benefit from potent platelet inhibition, which needs to be investigated in randomized trials.</jats:p></jats:sec>